Moderna’s Journey into Vaccine Development and Recent Challenges

On December 30, 2020, I found myself boarding the first of two flights to Boston, feeling a mix of anxiety and determination, all while double-masked. My destination? Moderna’s manufacturing site, which sits just outside the city, where I was set to receive my first vaccine dose.

Strangely enough, just a year prior, I was unaware of Moderna’s existence. But here I was, now an executive at the company, becoming part of a team grappling with a global crisis.

After the nurse gave me my first shot, we exchanged a glance, both of us feeling a wave of emotion. It was a moment filled with gratitude, underscored by a shared sense of hope that had emerged from a year full of collective suffering.

I vividly recall standing in that plant, which Moderna had fortuitously established less than two years before the pandemic hit. I marveled at the large containers brimming with vaccine material and mentioned to our head of manufacturing just how incredible the production levels were in that facility.

As we geared up for a visit from the governor, we discussed the highly skilled positions we were creating. There was an electric atmosphere in our labs near Kenmore Square, drawing brilliant minds from Cambridge’s vibrant research community.

Everything felt perfectly aligned—the science, the talent, and the community coming together in a way that felt natural for Massachusetts, a state with a rich history of vaccination innovation.

During meetings with the executive team, we made decisions that could accelerate programs which had been mere aspirations for years. With our newfound revenue-generating status, we could finally take some risks with our pipeline, guiding vaccines from the laboratory to clinical trials and eventually to patients.

We invested in a vaccine for cytomegalovirus (CMV), a virus that many might overlook but is actually a leading cause of hearing loss in infants. Perhaps even more emotional was our work on the mRNA vaccine for respiratory syncytial virus (RSV). For years, RSV research had hit a wall, and our approach held the promise of finally preventing countless infant respiratory deaths worldwide. This technology seemed to offer hope for a faster response to new health threats.

Yet, I watch in disbelief as that atmosphere of possibility is now overshadowed by a daunting reality. What once felt like a hopeful future is now stunted by regulatory unpredictability and, honestly, hostility.

Recently, the FDA declined to review Moderna’s application for its mRNA flu vaccine. They framed their decision around technicalities involving trial design and comparator standards, but I suspect there’s more to it than that.

This aligns with health secretary Robert F. Kennedy Jr.’s broader initiative, seemingly aimed at undermining confidence in vaccines and upending long-established guidelines. In his initial year, he’s promoted discredited claims regarding vaccine safety, minimized the impact of infectious diseases, criticized healthcare professionals, and dismantled vital elements of federal vaccine policy.

These actions send a troubling signal to innovators, investors, and the global community: it seems we’re less committed to leading in vaccine science than before.

Even before the FDA’s decision, Moderna’s CEO announced that the company would halt investments in new Phase 3 trials for infectious diseases. Projects targeting Epstein-Barr, herpes, and shingles—potentially groundbreaking tools in preventing long-term illness—are now sidelined. As he remarked at the World Economic Forum earlier this year, “You cannot make a return on investment if you don’t have access to the U.S. market.”

Timely regulatory guidance is essential. The journey to develop vaccines requires significant financial risk, complex supply chains, and years of investment. Companies take these risks under the assumption that the standards will be rigorous yet stable. When regulations feel like they’re built on shifting interpretations rather than sound scientific reasoning, it creates an unsettling atmosphere.

This isn’t just an abstract risk. The U.S. has historically been a leader in vaccine innovation, not merely thanks to our scientific expertise but also due to a trusted regulatory framework. As that trust wanes, investments are likely to follow suit.

If we make it difficult to develop next-generation vaccines here, companies will still find ways to innovate, just in different parts of the world. Unfortunately, that means Americans could be left behind.

It’s important to remember that the industry isn’t the enemy.

Throughout my career, working with major vaccine manufacturers, I saw colleagues approach their work with a public health mindset every day. The pharmaceutical sector is not the adversary. When businesses thrive, public health benefits in return. It’s a mutually beneficial relationship, not some grand conspiracy.

When we allow bias to overshadow scientific evidence, when we selectively use data to back predetermined outcomes, and when technical rulings cloak ideological skepticism, the fallout spreads far and wide. Public health relies on institutions that adhere to evidence consistently—not just when it suits them.

The repercussions of neglecting leadership in this arena won’t be visible in today’s headlines. They’ll manifest as preventable illnesses, unnecessary infant deaths, and a nation less prepared for future health crises, all because we’ve failed to appreciate the innovation that has historically saved lives.